These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20932069)

  • 1. Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study.
    Frediani B
    Clin Drug Investig; 2011; 31(1):43-50. PubMed ID: 20932069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.
    Frediani B; Bertoldi I; Pierguidi S; Nicosia A; Picerno V; Filippou G; Cantarini L; Galeazzi M
    Clin Drug Investig; 2013 Mar; 33(3):193-8. PubMed ID: 23456672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M; Quarta L; Calcagnile F; Quarta E
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular clodronate therapy in postmenopausal osteoporosis.
    Rossini M; Braga V; Gatti D; Gerardi D; Zamberlan N; Adami S
    Bone; 1999 Feb; 24(2):125-9. PubMed ID: 9951781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R; Yarman S; Bayraktaroglu T; Boztepe H; Alagöl F
    Clin Drug Investig; 2007; 27(6):419-33. PubMed ID: 17506592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
    Radicioni M; Cremonesi G; Baraldi E; Leuratti C; Mariotti F
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):313-22. PubMed ID: 23357844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome.
    Tauchmanova L; Guerra E; Pivonello R; De Martino MC; De Leo M; Caggiano F; Lombardi G; Colao A
    J Endocrinol Invest; 2009 May; 32(5):390-4. PubMed ID: 19794285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
    Gnudi S; Lisi L; Fini M; Malavolta N
    Int J Tissue React; 2001; 23(1):33-7. PubMed ID: 11392061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
    Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
    Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women.
    Dominguez LJ; Galioto A; Ferlisi A; Alessi MA; Belvedere M; Putignano E; Costanza G; Bevilacqua M; Barbagallo M
    Age Ageing; 2005 Nov; 34(6):633-6. PubMed ID: 16267191
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
    del Puente A; Scognamiglio A; Itto E; Ferrara G; Oriente P
    J Rheumatol; 2000 Aug; 27(8):1980-3. PubMed ID: 10955341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.